This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
COVID-19 has been a trial-by-fire showing just how quickly drugs and vaccines can be developed under the right circumstances – but there is much to do to ensure this progress is not lost, said speakers at WIRED Health 2021, including the CEOs of BioNTech and BenevolentAI. .
After being hailed as a triumph of public-private drugdevelopment, Moderna’s partnership with the US government on its COVID-19 vaccine looks like it may descend into acrimony.
Data defines modern therapeutics, but this is almost uniquely confined to the clinical trial stages of drugdevelopment. In the UK, for example, more than half the public expressed an unwillingness to take a vaccine unless it had been tested for at least a year.
Late last year, pharmaphorum caught up with Dr Karen Mullen, chief medical officer and VP of clinical & medical affairs at global drugdevelopment consultancy Boyds. We talk a lot in clinical trials and drugdevelopment about benefit,” Dr Mullen said. But who is benefitting?
Tobolowsky — CDER, CBER, and the Oncology Center of Excellence recently published a final guidance document titled “ Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products ” as another part of its real-world evidence (“RWE”) Program.
As the emphasis of new drugdevelopment gravitates towards new, ground-breaking therapies and vaccines, the requirements of manufacturing sites, equipment and processes need to be appropriate for this new environment.
One of the most tragic was the thalidomide disaster, in which pregnant women prescribed the drug to treat morning sickness suffered severe birth defects. This made drugdevelopers realize that flaws in the manufacturing process could go unnoticed. By the late 1970s, the concept of process validation was introduced.
Key Points of Support Conciseness and Focus of Key Information The NHC supports the FDA’s emphasis on beginning the informed consent document with concise, focused presentations of key information. The importance of using plain language in health communications is well-documented in literature.
QbD principles are woven into regulatory guidance documents, primarily guidances Q8 to Q11 of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Since most biologics and biosimilars are large molecules, they may prove challenging to develop and manufacture on the large scale.
To better understand FDA’s approach in classifying postmarketing pregnancy studies as PMRs or PMCs, we reviewed all postmarketing requirements (PMRs) and postmarketing commitments (PMCs) related to maternal and fetal outcomes in FDA’s PMR/PMC database for drugs approved in the ten-year period from January 2014 through December 2023.
When COVID hit, the urgent need to accelerate drugdevelopment meant shrinking timelines from years to months, with no room for compromises on quality. The rest is history: vaccines were delivered worldwide in record time, saving millions of lives. Cloud computing was one of the facilitators of this shift.
As drugdevelopers consider oligos potential, they often explore innovations in chemical modifications and delivery systems to ensure these therapies reach their full potential. Jinpeng has over 10 years of experience in academia and industry and has supported the preclinical studies of hundreds of new drugs.
They primarily focus on improving the public health infrastructure, improving the development of treatment and vaccines, and coordinating federal response. These flexibilities and partnerships greatly increased the speed of research and development for COVID-19 testing, treatment, and vaccines.
The spectrum of such products includes new chemical entities (NCE), new drugs with new indications or new routes of administration or new dosage forms, modified or sustained release formulations, novel drug delivery forms, vaccines, medical devices, and in-vitro diagnostic medical devices.
“Clearly the number one challenge in 2022, as mandated by the EU GMP Guidelines for the Manufacture of Sterile Medicinal Products Annex 1 1 , is the development of a Contamination Control Strategy (CCS),” Tony Cundell noted. He warned, “Implementation of a CCS will require more than writing documents.”.
With that in mind, the 9th annual Pre-Filled Syringes East Coast conference will bring together leading industry experts representing big pharma and device developers to discuss the key drivers accelerating the expansion of the industry. Smart device developers. Training device developers. Drugdevelopers.
Pharmaceutical companies have been working on developingvaccines and other prophylactics for respiratory syncytial virus (RSV) since its discovery in 1956. Despite strong efforts and scientific advances, a safe and effective vaccine for RSV has yet to be approved for any patient population.
President Trump’s pick to be health secretary, is keeping his financial stake in major litigation against Merck over a widely used vaccine given to young people , according to The New York Times. The vaccine is administered to adolescents to prevent cervical and other cancers later in life. Kennedy Jr.,
The successful development and deployment of the mRNA-based COVID-19 vaccines has catalysed the biopharma industry and paved the way to expand this drug modality to new therapeutic areas. Excluding vaccines, there are five mRNA therapeutic products in clinical trial development as of November 2022.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content